A Phase 1 interventional study of 2mg KH607 tablets and 5mg KH607 tablets in Healthy, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-07.
Sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) stage. The primary objective was to evaluate the safety and tolerability of KH607 tablets in Chinese healthy volunteers.
This study consists of two parts: Part 1-SAD phase and Part 2- MAD phase. There will be eight cohorts in Part 1 and three cohorts in Part 2 of this study.
The SAD study will enroll approximately 58 HVs across 8 dose cohorts. The dose cohorts will include the following dose levels: 2 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50mg and 60 mg. All participants in Part 1 will be administered with a single oral dose of KH607 or its matching placebo under fasted condition.
Approximately 30 HVs will be enrolled in the multiple ascending dose study. The dose cohorts will include the following dose levels: 10 mg, 20 mg, 30 mg.At each cohort, 10 subjects will be randomized in a ratio of 8:2 to be receive KH607 or placebo once daily for continuous 7 days (QDx7d) in a double-blind manner.
Additionally, this study will explore the effect of food on the PK of a single oral administration of KH607 in one selected SAD cohort.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is the lead sponsor of 11 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject received a single KH607 tablets dose of 2mg KH607 tablets or matching placebo.
Drug: 2mg KH607 tablets
Subject received a single KH607 tablets dose of 5mg KH607 tablets or matching placebo.
Drug: 5mg KH607 tablets
Subject received a single KH607 tablets dose of 10mg KH607 tablets or matching placebo.
Drug: 10mg KH607 tablets
Subject received a single KH607 tablets dose of 20mg KH607 tablets or matching placebo.
Drug: 20mg KH607 tablets
Subject received a single KH607 tablets dose of 30mg KH607 tablets or matching placebo.
Drug: 30mg KH607 tablets
Subject received a single KH607 tablets dose of 40mg KH607 tablets or matching placebo.
Drug: 40mg KH607 tablets
Subject received a single KH607 tablets dose of 50mg KH607 tablets or matching placebo.
Drug: 50mg KH607 tablets
Subject received a single KH607 tablets dose of 60mg KH607 tablets or matching placebo.
Drug: 60mg KH607 tablets
Subject received 10mg KH607 or matching placebo, oncely daily from Day 1 to Day 7.
Drug: 10mg KH607 tablets
Subjects receive 20mg KH607 or matching placebo, once daily from Day 1 to Day 7.
Drug: 20mg KH607 tablets
Subjects receive 30mg KH607 or matching placebo, once daily from Day 1 to Day 7.
Drug: 30mg KH607 tablets
Subject receive KH607 tablets or placebo orally single dose.
Subject receive KH607 tablets or placebo orally single dose.
Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Subject receive KH607 tablets or placebo orally single dose.
Subject receive KH607 tablets or placebo orally single dose.
Subject receive KH607 tablets or placebo orally single dose.
12-lead ECGs
Using a standard 12-lead ECG machine that automatically calculates heart rate and measures PR interval, RR interval, QRS interval, QT interval and QTc interval. ECGs will be reviewed by the Investigator on an ongoing basis as safety assessments.
Time frame: Screening up to Part 1 Days, Part 2 Day14.
Physical Examination
Time frame: Screening up to Part 1 Days, Part 2 Day14.
12-lead ECGs
Using a standard 12-lead ECG machine that automatically calculate heart rate and measures PR interval, RR interval, QRS interval, QT interval, QTc interval. ECGs will be reviewed by the Investigator on an ongoing basis as safety assessments.
Time frame: Screening up to Part 2 Day14.
Stanford Sleepiness Scale
Participants rate their current sleepiness on a scale of 1 to 7, where scale of 1 indicates feeling active, vital, alert, or wide awake. Scale of 7 indicates no longer fighting sleep, sleep onset soon, and having dream-like thoughts.
Time frame: Screening up to Part 1 Day3,Part 2 Day14.
Modified Observer's Assessment of Alertness/Sedation scale
The MOAA/S ranges from 0 to 5, with a score of 5 defined as awake or minimally sedated, and a score of 0 defined as general anaesthesia.
Time frame: Screening up to Part 1 Day3,Part 2 Day14.
Columbia-Suicide Severity Rating Scale
The C-SSRS scale consists of three subscales: suicidal ideation, intensity of ideation and suicidal behavior.
Time frame: Screening up to Part 1 Day3,Part 2 Day14.
Observed maximum plasma concentration (Cmax)
Time frame: Up to 48 hours after dosing in Part 1.
Time to reach maximum plasma concentration (Tmax)
Time frame: Up to 48 hours after dosing in Part 1.
Elimination Halflife (T1/2)
Time frame: Up to 48 hours after dosing in Part 1.
Area under the concentration-time curve from time zero to last time of quantifiable concentration(AUC0-t)
Time frame: Up to 48 hours after dosing in Part 1.
Apparent Distribution Volume (Vd)
Time frame: Up to 48 hours after dosing in Part 1.
Apparent Total Plasma Clearance (CL)
Time frame: Up to 48 hours after dosing in Part 1.
Elimination Rate Constant (Kel)
Time frame: Up to 48 hours after dosing in Part 1.
Mean Residence Time(MRT)
Time frame: Up to 48 hours after dosing in Part 1.
Steady-state valley concentration(Css,min)
Time frame: Up to 24 hours after Day7 dosing in Part 2.
Steady-state peak concentration(Css,max)
Time frame: Up to 24 hours after Day7 dosing in Part 2.
Mean steady-state blood concentration(Css,av)
Time frame: Up to 24 hours after Day7 dosing in Part 2.
Steady state area under the curve(AUC0-tau)
Time frame: Up to 24 hours after Day7 dosing in Part 2.
Accumulation Index(Rac)
Time frame: Up to 24 hours after Day7 dosing in Part 2.
Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. →